Imagion Biosystems Limited
IBXXF
$0.01
$0.00-10.71%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.38% | -95.51% | -98.48% | -98.49% | -75.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.38% | -95.51% | -98.48% | -98.49% | -75.94% |
| Cost of Revenue | 2,104.05% | 2,039.47% | 78.58% | 75.32% | -97.76% |
| Gross Profit | -251.18% | -246.54% | -143.74% | -142.92% | -22.35% |
| SG&A Expenses | 17.97% | 14.33% | -70.35% | -70.90% | -84.91% |
| Depreciation & Amortization | -44.00% | -46.15% | -98.89% | -98.89% | -98.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 183.60% | 174.90% | -55.25% | -56.09% | -90.29% |
| Operating Income | -1,458.95% | -1,417.58% | -21.35% | -19.05% | 103.87% |
| Income Before Tax | -393.75% | -378.56% | -5.78% | -3.80% | 88.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -393.75% | -378.56% | -5.78% | -3.80% | 88.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -393.75% | -378.56% | -5.78% | -3.80% | 88.73% |
| EBIT | -1,458.95% | -1,417.58% | -21.35% | -19.05% | 103.87% |
| EBITDA | -1,293.06% | -820.95% | -107.10% | -103.28% | 105.07% |
| EPS Basic | 19.35% | 21.88% | 83.12% | 83.12% | 93.50% |
| Normalized Basic EPS | 21.05% | 25.00% | 82.29% | 83.33% | 93.62% |
| EPS Diluted | 19.35% | 21.88% | 82.47% | 83.12% | 93.50% |
| Normalized Diluted EPS | 21.05% | 25.00% | 82.29% | 83.33% | 93.62% |
| Average Basic Shares Outstanding | 517.65% | 517.65% | 516.73% | 516.73% | 74.97% |
| Average Diluted Shares Outstanding | 517.65% | 517.65% | 516.73% | 516.73% | 74.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |